Abstract
Background:
Toxicity associated with immunosuppression and conditioning regimens represents a common cause of neurological complications after allogeneic stem cell transplantation.
Case report:
We present a 56-year-old female patient with refractory acute lymphoblastic leukemia undergoing reduced-intensity conditioning with fludarabine, BCNU and melphalan followed by matched-sibling allogeneic stem cell transplantation. Under immunosuppressive treatment with cyclosporine A (CSA) the patient developed early-onset (day +33) and ultimately fatal leukoencephalopathy.
Discussion:
As fludarabine and CSA represent two key substances of today's reduced-intensity conditioning regimens we raise the question of whether CSA, fludarabine or a combination of both led to this outcome and discuss differential diagnoses.
MeSH terms
-
Antineoplastic Agents
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Carmustine / administration & dosage
-
Carmustine / adverse effects
-
Combined Modality Therapy
-
Cyclosporine / administration & dosage
-
Cyclosporine / adverse effects*
-
Demyelinating Diseases / chemically induced*
-
Demyelinating Diseases / diagnosis
-
Fatal Outcome
-
Female
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects
-
Melphalan / administration & dosage
-
Melphalan / adverse effects
-
Middle Aged
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery*
-
Risk Assessment
-
Stem Cell Transplantation
-
Vidarabine / administration & dosage
-
Vidarabine / adverse effects
-
Vidarabine / analogs & derivatives*
Substances
-
Antineoplastic Agents
-
Immunosuppressive Agents
-
Cyclosporine
-
Vidarabine
-
fludarabine
-
Melphalan
-
Carmustine